KEYNOTE-006: a success in melanoma, but a long way to go

Lancet. 2017 Oct 21;390(10105):1816-1817. doi: 10.1016/S0140-6736(17)31816-0. Epub 2017 Aug 16.

Authors

Kilian Wistuba-Hamprecht¹, Graham Pawelec²

Affiliations

¹ Department of Dermatology, University Medical Centre Tuebingen, Centre for Medical Research, 72074 Tuebingen, Germany. Electronic address: kilian.wistuba-hamprecht@uni-tuebingen.de.
² Department of Internal Medicine II, University Medical Centre Tuebingen, Centre for Medical Research, 72074 Tuebingen, Germany; Health Sciences North Research Institute, Sudbury, ON Canada.

PMID: 28822577
DOI: 10.1016/S0140-6736(17)31816-0

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Ipilimumab
Melanoma*

Substances

Antibodies, Monoclonal, Humanized
Ipilimumab
pembrolizumab